Abstract

Although transurethral resection of bladder tumor is the golden standard for the treatment of non-muscle invasive bladder cancer, this surgical procedure still has some serious drawbacks. For example, piecemeal resection of tumor tissue results in exfoliated tumor cells dissemination and implantation, and fragmented tumor specimens make it difficult for pathologists to accurately assess the pathological stage and histologic grade. En bloc tumor resection follows the basic principle of oncological surgery and provides an intact tumor specimen containing detrusor muscle for pathologists to make accurate histopathological assessment. However, there is no robust clinical evidence that en bloc tumor resection is superior to conventional resection in terms of oncological outcomes. Considering the high recurrence rate, small or occult tumor lesions may be overlooked and incomplete tumor resection may occur during white light cystoscopy-assisted transurethral resection. Molecular fluorescent tracers have the ability to bind tumor cells with high sensitivity and specificity. Optical molecular imaging mediated by it can detect small or occult malignant lesions while minimizing the occurrence of false-positive results. Meanwhile, optical molecular imaging can provide dynamic and real-time image guidance in the surgical procedure, which helps urologists to accurately determine the boundary and depth of tumor invasion, so as to perform complete and high-quality transurethral tumor resection. Integrating the advantages of these two technologies, optical molecular imaging-assisted en bloc tumor resection shows the potential to improve the positive detection rate of small or occult tumor lesions and the quality of transurethral resection, resulting in high recurrence-free and progression-free survival rates.

Highlights

  • Bladder cancer (BC) is the tenth most common cancer disease worldwide with 474 000 new incident cases and 197 000 deaths annually, and it is the second most common malignant disease of the urinary system after prostate cancer [1]

  • The quality of transurethral tumor resection plays an important role in histopathological assessment and treatment decision-making, which affects the prognosis of the disease

  • Piecemeal resection of tumor tissue leads to the dissemination and implantation of exfoliated tumor cells, which goes against the recognized principle of oncological surgery and contributes to increases in the rate of tumor recurrence [6,7,8]

Read more

Summary

INTRODUCTION

Bladder cancer (BC) is the tenth most common cancer disease worldwide with 474 000 new incident cases and 197 000 deaths annually, and it is the second most common malignant disease of the urinary system after prostate cancer [1]. About 75% of newly diagnosed BC cases present as a lesion confined to the mucosa or submucosa, collectively referred to as non-muscle invasive bladder cancer (NMIBC) [2] For these patients, transurethral resection of bladder tumor (TURBT) combined with personal intravesical chemotherapy or immunotherapy that is tailored to tumor risk stratification is recommended as the routine treatment model by the major international guidelines [2,3,4,5]. Through more controllable and precise surgical procedures of transurethral resection, the risk of perioperative complications in ERBT, such as blood loss, ONR, and BP, is reduced compared with conventional TURBT. As a “no touch” technique for the treatment of NMIBC, shows the potential to minimize the number of exfoliated tumor cells and reduce the risk of tumor cells entering the blood circulation [55].

39 Mean 12 mo
Findings
CONCLUSIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call